Stock HRMY HARMONY BIOSCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Real-time Estimate Cboe BZX
Other stock markets
 03:35:46 2024-05-20 pm EDT 		5-day change 1st Jan Change
29.69 USD +2.27% Intraday chart for Harmony Biosciences Holdings, Inc. -1.77% -8.10%
Apr. 30 Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise MT
Apr. 30 Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy
AQ
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise
MT
Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.
CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78
MT
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
GL
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024
CI
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
PR
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PR
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
AQ
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy
MT
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms
MT
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
PR
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome
CI
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PR
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing
MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:35 PM
Harmony Biosciences Certified as a Great Place to Work for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth
AQ
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. News Harmony Biosciences Holdings, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW